Project Name: Lipid Hub for Community CVD Hub Model of Care 

Project Summary:

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimization of patients with atherosclerotic cardiovascular disease (ASCVD) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, in response to the needs of the CW Partner. 

Planned Milestones:

  • Lipid Management pathway/protocol development.
  • Collection of baseline data, in line with the expected project outcome measurements.
  • Confirmation that recruitment in process.
  • Collection & submission of 3 months clinical activity data.
  • Confirmation that recruitment is complete and all recruited project staff are fully trained.
  • Collection & submission of 6 months clinical activity data.
  • Collection & submission of 9 months clinical activity data.
  • Collection & submission of 12 months clinical activity data.
  • Development of business case to ongoing utilisation of CVD Hubs piloted in this project.
  • Analysis of CWP data, submission of Final CWP Report, Submission of Outcomes Summary.

Expected Benefits:

For the Patient:

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.
  • Enhanced experience and counselling around ASCVD with ongoing management of the condition. 
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events.
  • Easier access to lipid management care closer to home in the primary care setting.
  • The additional capacity will provide additional time and support for lipid management, focusing of patients who may have previously not attended GP appointments or been lost to follow-up. This help to level health inequalities within the practice and, ultimately, in a wider setting.

For the CW Partner:

  • Increased proportion of ASCVD patients reviewed by primary care.
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home.
  • Reduction in ASCVD referral rates to secondary care.
  • Increased proportion of patients receiving guideline-directed pharmacotherapy.
  • Insight into benefits of novel primary care led lipid management clinics and demonstration of benefit via development of business case for substantive funding.
  • Support aligned to NHS Long Term Plan, CDVPREVENT, and Network Contract DES.
  • Opportunity to show the impact of the CWP to create lasting change in lipid management within Nimbuscare.

For Novartis: 

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines.
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life by supporting high quality Collaborative Working with the NHS which addresses the problem of health inequalities.
  • Ethical, professional, and transparent relationship between Novartis and the NHS.

Start Date & Duration: November 2023 for 14 months